Perspective

Scroll through any tech feed today and you’d think we’re on the brink of telepathy. Neuralink is streaming chess moves from a paralyzed patient’s brain, Synchron is threading stentrodes into cortical veins, and every new inner-speech decoding paper gets spun as “mind reading.” At the same time, consumer EEG headsets and neuro-gadgets are flooding the market, promising focus, calm, and hands-free control. Behind the headlines, money is pouring in: nine-figure rounds for the us

Few people dare to start a company, and even fewer attempt it in a technically complex field like neurotechnology. Yet Dr Hamed Bahmani has now done it three times. After launching a clinical-stage company focused on myopia and another targeting Alzheimer’s through the visual system, he is doubling down on complexity. His latest venture has just emerged out of stealth, but early hints suggest it draws on decades spent at the forefront of neuro-innovation. Born in Iran, Bahman

At first, there was the space race. Then came a scramble for AI. Now billionaires are flocking to the neurotech arena. Increasingly, ultra-rich investors are taking stakes in brain-computer interface startups. The concept of reading the mind and connecting it to the outside world was long thought impossible. But now that the question is no longer if  it will reach the market but when , tech moguls are looking to have their names attached to the first commercial devices. The b

Digital phenotyping is reshaping neurology, passively detecting early disease signals, stratifying patients into precise subgroups, and opening up possibilities for precision medicine. But its real-world promise depends on more than just collecting data. The true challenge lies in deciding which signals are worth capturing, grounding them in validated neuroscience, and making them actionable in the clinic. This is the space where Rune Labs has established itself as a leader.

The BCI field is picking up momentum. At Stanford, researchers recently showed it is possible to decode attempted speech with vocabularies in the hundreds of thousands and error rates below 5%. At UCLA, new work with EEG and AI copilots suggests that less invasive approaches may also enable practical interfaces. Meanwhile, companies like Neuralink, Precision Neuroscience, and Synchron are pushing their devices closer to real-world use, whether through high-bandwidth implants

Venture capital has played a defining role in shaping the trajectory of neurotech, yet many scientist-founders still find the funding...